Analytical approach:
The analysis was an economic evaluation carried out alongside a single clinical study. A lifetime horizon was used and the authors reported that a health care perspective was adopted.
Effectiveness data:
The clinical and effectiveness data were from a before-and-after analysis. One hundred and forty-seven adult patients who were offered a bone-anchored hearing device in one city were sent a questionnaire prior to implantation of the device and 89 questionnaires were returned. Patients were sent a second questionnaire following implantation of the device and 70 of these were completed. The main measure of effectiveness was the health utility score.
Monetary benefit and utility valuations:
Utility values were obtained from the patients included in the clinical study and were derived using the Health Utility Index (HUI) questionnaire Mark 2 and Mark 3. These were used in preference to EQ-5D due to their hearing domain: Mark 2 combined hearing with vision and speech and Mark 3 evaluated hearing separately.
Measure of benefit:
The measure of benefit was the quality-adjusted life-year (QALY) discounted at an annual rate of 3.5%.
Cost data:
The economic analysis included costs of surgery, the bone-anchored hearing device and its subsequent maintenance. Resource use data were derived from patient records. Cost data were obtained from the hospital that provided the treatment. The price year was 2008. Costs were discounted at an annual rate of 3.5%.
Analysis of uncertainty:
Nonparametric bootstrapping was used to examine uncertainty in model outputs. Cost-effectiveness acceptability curves were generated for various willingness-to-pay thresholds. One-way sensitivity analysis was carried out on the discount rate.